These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 21692140)
41. Managing the risks of therapeutic products: proceedings of a workshop. Kramer JM Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):619-28. PubMed ID: 15641121 [TBL] [Abstract][Full Text] [Related]
42. Criteria used by Health Canada's Product Safety bureau to determine whether or not regulations are needed to address the hazards associated with a given consumer product. Fortin Y Inj Prev; 1998 Dec; 4(4):259-60. PubMed ID: 9887413 [No Abstract] [Full Text] [Related]
43. A pilot study to compare natural health product-drug interactions in two databases in Canada. Faubert G; Lebel D; Bussières JF Pharm World Sci; 2010 Apr; 32(2):179-86. PubMed ID: 20077138 [TBL] [Abstract][Full Text] [Related]
44. Patients' perceptions and use of natural health products. Barry AR Can Pharm J (Ott); 2018; 151(4):254-262. PubMed ID: 30237840 [TBL] [Abstract][Full Text] [Related]
45. Patterns of natural health product use at an outpatient heart function clinic. Tress K; Chiu A; Kwan L; Gordon W Can Pharm J (Ott); 2023; 156(2):94-101. PubMed ID: 36969309 [TBL] [Abstract][Full Text] [Related]
46. Clinical risk management of interactions between natural products and drugs. De Smet PA; Floor-Schreudering A; Bouvy ML; Wensing M Curr Drug Metab; 2008 Dec; 9(10):1055-62. PubMed ID: 19075622 [TBL] [Abstract][Full Text] [Related]
47. Interactions of natural health products with biomedical cancer treatments. Seely D; Oneschuk D Curr Oncol; 2008 Aug; 15 Suppl 2(Suppl 2):s109.es81-s10.es6. PubMed ID: 18769615 [TBL] [Abstract][Full Text] [Related]
48. Challenges product list issued by Food and Drug Administration. Ohio State Med J; 1971 Mar; 67(3):202. PubMed ID: 5543469 [No Abstract] [Full Text] [Related]
49. In a Circular Issued by the Board of Health. Halls J Health; 1885 Oct; 32(10):8. PubMed ID: 36491059 [No Abstract] [Full Text] [Related]
50. Epidemiology of NHP-drug interactions: identification and evaluation. Brulotte J; Vohra S Curr Drug Metab; 2008 Dec; 9(10):1049-54. PubMed ID: 19075621 [TBL] [Abstract][Full Text] [Related]
51. Postmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectives. Murty M Can J Physiol Pharmacol; 2007 Sep; 85(9):952-5. PubMed ID: 18066142 [TBL] [Abstract][Full Text] [Related]
52. Self-reported use of natural health products: a cross-sectional telephone survey in older Ontarians. Levine MA; Xu S; Gaebel K; Brazier N; Bédard M; Brazil K; Lohfeld L; MacLeod SM Am J Geriatr Pharmacother; 2009 Dec; 7(6):383-92. PubMed ID: 20129259 [TBL] [Abstract][Full Text] [Related]
53. Natural health product use in Canada: analysis of the National Population Health Survey. Singh SR; Levine MA Can J Clin Pharmacol; 2006; 13(2):e240-50. PubMed ID: 16921199 [TBL] [Abstract][Full Text] [Related]
54. Regulation of natural health products in Canada. Smith A; Jogalekar S; Gibson A J Ethnopharmacol; 2014 Dec; 158 Pt B():507-10. PubMed ID: 24969823 [TBL] [Abstract][Full Text] [Related]
55. A descriptive study evaluating Health Canada's risk communications. Bateman J; Charrois TL; Gardiner P; Vohra S Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1104-9. PubMed ID: 21692140 [TBL] [Abstract][Full Text] [Related]